Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Avipritinib, crenolanib, pazopanib and other type I tyrosine...
| Class:Id | Summation:9674504 |
|---|---|
| _displayName | Avipritinib, crenolanib, pazopanib and other type I tyrosine... |
| _timestamp | 2020-02-25 20:26:15 |
| created | [InstanceEdit:9674503] Rothfels, Karen, 2020-01-13 |
| modified | [InstanceEdit:9677032] Rothfels, Karen, 2020-02-25 |
| text | Avipritinib, crenolanib, pazopanib and other type I tyrosine kinase inhibitors bind to the active form of the PDGF receptors and prevent their trans-autophosphorylation (reviewed in Roskoski, 2018; Klug et al, 2018; Papadopoulos and Lennartsson, 2016). PDGFRA receptors with mutations that strongly promote the active state, such as mutations in the kinase domain or the gatekeeper mutation T674I tend to be sensitive to type I TKIs. In contrast, the extracellular domain mutation Y288C is resistant to type I TKIs (Ip et al, 2018; reviewed in Roskoski, 2018; Klug et al, 2018). |
| (summation) | [Reaction:9674427] PDGFR mutants bind type I TKIs [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Avipritinib, crenolanib, pazopanib and other type I tyrosine... (9674504)
